| Bioactivity | PKCε inhibitor peptide,myristoylated (Myr‐PKC?-) is a cell permeable myristic acid conjugated PKC? peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs)[1]. |
| Target | PKCε |
| Name | PKCε inhibitor peptide,myristoylated |
| Sequence | {Myr}-Glu-Ala-Val-Ser-Leu-Lys-Pro-Thr |
| Shortening | {Myr}-EAVSLKPT |
| Formula | C51H91N9O14 |
| Molar Mass | 1054.32 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Castro J, et al. The Effects of Novel Myristoylated PKC Epsilon Peptide Modulators on Real‐Time Nitric Oxide Release in Human Umbilical Vein Endothelial Cells. The FASEB Journal, 2020, 34(S1): 1-1. |
PKCε inhibitor peptide,myristoylated
CAS: F: C51H91N9O14 W: 1054.32
PKCε inhibitor peptide,myristoylated (Myr‐PKC?-) is a cell permeable myristic acid conjugated PKC? peptide inhibitor t
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.